CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)
Latest Information Update: 24 Oct 2025
At a glance
- Drugs Semaglutide (Primary)
- Indications Alcohol-related disorders
- Focus Therapeutic Use
- Acronyms CRAVE
Most Recent Events
- 24 Oct 2025 New trial record